Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 14

Metabolic Syndrome and Psoriasis: A Case–Control Study in Kabul, Afghanistan

Authors Aalemi AK, Bahain MB, Hamdard AG

Received 11 February 2021

Accepted for publication 11 March 2021

Published 30 March 2021 Volume 2021:14 Pages 1465—1471

DOI https://doi.org/10.2147/DMSO.S305806

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Ming-Hui Zou


Ahmad Khalid Aalemi,1,2 Mohammad Barin Bahain,3 Abdul Ghafar Hamdard2

1Department of Epidemiology, Kabul University of Medical Sciences, Kabul, Afghanistan; 2Department of Dermatology, Maiwand Teaching Hospital, Kabul University of Medical Sciences, Kabul, Afghanistan; 3Department of Pharmacology, Kabul University of Medical Sciences, Kabul, Afghanistan

Correspondence: Ahmad Khalid Aalemi
Department of Epidemiology, Kabul University of Medical Sciences, Kabul, 1001, Afghanistan
Tel +93747947581
Email [email protected]

Background: Psoriasis is a chronic inflammatory disease that is not limited to the skin. Recently, numerous studies have shown a positive association between metabolic syndrome and psoriasis.
Objective: The current study aimed to examine the association of metabolic syndrome with psoriasis in an Afghan population.
Methods: This was a case– control study including 114 patients with psoriasis and 114 controls aged ≥ 18 years admitted to the dermatology department of Maiwand Teaching Hospital in Kabul, Afghanistan. Height, weight, blood pressure, and waist circumference were measured in all subjects. Blood glucose, triglyceride, cholesterol, and high-density lipoprotein cholesterol levels were tested following overnight fasting. The modified National Cholesterol Education Program – Adult Treatment Panel III criteria were used for the diagnosis of metabolic syndrome.
Results: In total, 51.8% of the cases and 44.7% of the controls were male. The average age of participants was 33.4± 13.1 years in the case group and 41.1± 15.4 years in the control group. The average duration of disease for psoriasis was 4.2 years with 5.6 years SD. The average PASI was 10.8 with 5.1 SD. More than half of the cases (62.3%) had moderate to severe psoriasis and 37.7% had mild psoriasis. The prevalence of metabolic syndrome was higher among patients with psoriasis compared to controls (36.8% vs 21.1%) with OR of 2.18 (p=0.009). In addition, overweight/obesity was more prevalent among cases compared to controls (65.8% vs 41.2%) with OR of 2.74 (p< 0.001), whereas the waist circumference was not significantly different between the two groups. Furthermore, the mean levels of total cholesterol, triglyceride, and fasting blood glucose were also higher among patients with psoriasis compared to controls.
Conclusion: The results of the study confirm the association between psoriasis and metabolic syndrome. Hence, screening psoriatic patients for metabolic syndrome should be considered.

Keywords: psoriasis, metabolic syndrome, hypertension, dyslipidemia, obesity, case–control study, Kabul

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]